文献速递基础与转化研究新药、器械与细胞基因治疗研发

基质重编程克服RAS-MAPK抑制耐药以改善胰腺癌对细胞毒和免疫治疗的应答

Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.
PubMed 文献 · Sci Transl Med · 2024-10-23

在胰腺导管腺癌(PDAC)小鼠模型和患者组织中,长期黏着斑激酶(FAK)抑制剂治疗导致RAS/MAPK通路过度激活;同时抑制FAK(VS-4718)与RAF-MEK(avutometinib)可在多个PDAC小鼠模型中抑制肿瘤生长并延长生存。癌相关成纤维细胞(CAF)通过抑制RAF-MEK抑制对MYC的下调导致耐药,FAK抑制重编程CAF以抑制FGF1产生;联合化疗可致肿瘤消退、减少肝转移并改善生存,FAK与RAF-MEK抑制联合改善抗肿瘤免疫并增强化疗引发的T细胞应答启动。

要点

  • 长期FAK抑制剂治疗在PDAC小鼠模型和患者组织中导致RAS/MAPK通路过度激活。
  • FAK抑制(VS-4718)联合RAF-MEK抑制(avutometinib)在多个PDAC小鼠模型中抑制肿瘤生长并延长生存。
  • CAF通过抑制RAF-MEK抑制对MYC的下调导致耐药,FAK抑制重编程CAF以抑制FGF1产生。

核心结论

  • 基质重编程(FAK抑制)可克服PDAC对RAS-MAPK抑制的耐药,联合RAF-MEK抑制在KRAS驱动PDAC小鼠模型中抑制肿瘤生长并延长生存。
  • FAK与RAF-MEK抑制联合化疗可致肿瘤消退、减少肝转移并改善生存,且FAK与RAF-MEK抑制联合改善抗肿瘤免疫并增强化疗引发的T细胞应答启动。
  • 这些发现为正在进行的评估avutometinib与defactinib联合吉西他滨和白蛋白结合型紫杉醇治疗PDAC患者的临床试验提供了依据。

研究设计与样本

  • 研究使用PDAC小鼠模型和PDAC患者组织,评估FAK抑制剂(VS-4718)与RAF-MEK抑制剂(avutometinib)单用或联合的效应。

主要发现

  • 长期FAK抑制剂治疗在PDAC小鼠模型和PDAC患者组织中导致RAS/MAPK通路过度激活。
  • FAK抑制(VS-4718)联合RAF-MEK抑制(avutometinib)在多个PDAC小鼠模型中诱导肿瘤生长抑制并增加生存。
  • 在肿瘤微环境中,癌相关成纤维细胞(CAF)损害RAF-MEK抑制对PDAC细胞中MYC的下调,导致耐药。
  • FAK抑制重编程CAF以抑制FGF1产生,而FGF1可驱动对RAF-MEK抑制的耐药。
  • 在KRAS驱动PDAC小鼠模型中,FAK与RAF-MEK抑制联合化疗导致肿瘤消退、肝转移减少并改善生存。

临床怎么用

  • 作者认为这些发现为正在进行的评估avutometinib与defactinib联合吉西他滨和白蛋白结合型紫杉醇治疗PDAC患者的临床试验提供了依据。
  • 作者认为这些发现可能提示联合基质靶向和肿瘤靶向治疗的进一步路径。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is often resistant to therapy. An immune suppressive tumor microenvironment (TME) and oncogenic mutations in KRAS have both been implicated as drivers of resistance to therapy. Mitogen-activated protein kinase (MAPK) inhibition has not yet shown clinical efficacy, likely because of rapid acquisition of tumor-intrinsic resistance. However, the unique PDAC TME may also be a driver of resistance. We found that long-term focal adhesion kinase (FAK) inhibitor treatment led to hyperactivation of the RAS/MAPK pathway in PDAC cells in mouse models and tissues from patients with PDAC. Concomitant inhibition of both FAK (with VS-4718) and rapidly accelerated fibrosarcoma and MAPK kinase (RAF-MEK) (with avutometinib) induced tumor growth inhibition and increased survival across multiple PDAC mouse models. In the TME, cancer-associated fibroblasts (CAFs) impaired the down-regulation of MYC by RAF-MEK inhibition in PDAC cells, resulting in resistance. By contrast, FAK inhibition reprogramed CAFs to suppress the production of FGF1, which can drive resistance to RAF-MEK inhibition. The addition of chemotherapy to combined FAK and RAF-MEK inhibition led to tumor regression, a decrease in liver metastasis, and improved survival in KRAS-driven PDAC mouse models. Combination of FAK and RAF-MEK inhibition alone improved antitumor immunity and priming of T cell responses in response to chemotherapy. These findings provided the rationale for an ongoing clinical trial evaluating the efficacy of avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in patients with PDAC and may suggest further paths for combined stromal and tumor-targeting therapies.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Liu X, Baer JM, Stone ML, et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Sci Transl Med. 2024. PMID: 39441902. doi:10.1126/scitranslmed.ado2402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。